OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SAE58

Shufersal Ltd

Food Retail & DistributionVerified

Shufersal maintains a capital structure with a debt-to-equity ratio of 1.44, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.85, suggesting potential short-term liquidity constraints. Additionally, the firm's cash and equivalents amount to 1.34 billion ILS, which is insufficient to cover its long-term debt of 5.9 billion ILS, resulting in a net cash deficit. In terms of profitability, Shufersal's return on equity (ROE) stands at 17.32%, significantly outperforming the industry median for food retailers. Its return on assets (ROA) of 4.86% also reflects a strong asset utilization efficiency, although it is slightly below the top quartile of the industry. The company's operating income of 1.1 billion ILS and net income of 711 million ILS demonstrate robust earnings power relative to its revenue base of 14.49 billion ILS. Geographically, Shufersal's operations are concentrated in Israel, with no material international revenue disclosed. The company's segmental breakdown is not publicly detailed, but its primary revenue streams are derived from retail grocery and drug sales. This concentration exposes the company to local economic and regulatory risks. Looking ahead, Shufersal is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. The company's capital expenditure of -271 million ILS indicates a reduction in investment, which may signal a focus on cost optimization rather than expansion. Analysts have assigned a mean price target of 53.05 ILS, with a median of 53.05 ILS, reflecting a consensus of moderate optimism. The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key liquidity flag is the negative net cash position after accounting for total debt, which could necessitate additional financing in the near term. However, the low dilution risk suggests that the company is unlikely to issue new shares in the near future, preserving shareholder value. Recent events, including the latest financial filings and analyst reports, indicate a stable operational environment for Shufersal. The company has not disclosed any material legal or regulatory issues, and its financial performance remains consistent with historical trends.

30-day price · SAE+393.00 (+8.6%)
Low$4348.00High$5080.00Close$4984.00As of25 May, 00:00 UTC
Profile
CompanyShufersal Ltd
TickerSAE.TA
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. Shufersal Ltd operates as a leading food and drug retailer in Israel, generating revenue primarily through the sale of groceries, household goods, and pharmaceutical products.

Classification. Shufersal is classified under the Consumer Non-Cyclicals economic sector, specifically in the Food & Drug Retailing business sector, with a high confidence level of 0.92.

Shufersal maintains a capital structure with a debt-to-equity ratio of 1.44, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.85, suggesting potential short-term liquidity constraints. Additionally, the firm's cash and equivalents amount to 1.34 billion ILS, which is insufficient to cover its long-term debt of 5.9 billion ILS, resulting in a net cash deficit. In terms of profitability, Shufersal's return on equity (ROE) stands at 17.32%, significantly outperforming the industry median for food retailers. Its return on assets (ROA) of 4.86% also reflects a strong asset utilization efficiency, although it is slightly below the top quartile of the industry. The company's operating income of 1.1 billion ILS and net income of 711 million ILS demonstrate robust earnings power relative to its revenue base of 14.49 billion ILS. Geographically, Shufersal's operations are concentrated in Israel, with no material international revenue disclosed. The company's segmental breakdown is not publicly detailed, but its primary revenue streams are derived from retail grocery and drug sales. This concentration exposes the company to local economic and regulatory risks. Looking ahead, Shufersal is projected to maintain a stable revenue trajectory, with no significant growth or contraction expected in the next fiscal year. The company's capital expenditure of -271 million ILS indicates a reduction in investment, which may signal a focus on cost optimization rather than expansion. Analysts have assigned a mean price target of 53.05 ILS, with a median of 53.05 ILS, reflecting a consensus of moderate optimism. The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key liquidity flag is the negative net cash position after accounting for total debt, which could necessitate additional financing in the near term. However, the low dilution risk suggests that the company is unlikely to issue new shares in the near future, preserving shareholder value. Recent events, including the latest financial filings and analyst reports, indicate a stable operational environment for Shufersal. The company has not disclosed any material legal or regulatory issues, and its financial performance remains consistent with historical trends.
Key takeaways
  • Shufersal's ROE of 17.32% and ROA of 4.86% indicate strong profitability and asset efficiency.
  • The company's debt-to-equity ratio of 1.44 suggests a moderate debt load, but its current ratio of 0.85 highlights liquidity concerns.
  • Shufersal's operations are concentrated in Israel, exposing it to local economic and regulatory risks.
  • Analysts project a stable revenue trajectory with a mean price target of 53.05 ILS.
  • The company's low dilution risk and stable capital expenditure suggest a conservative financial strategy.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyILS
Revenue$14.49B
Gross profit$4.37B
Operating income$1.10B
Net income$711.0M
R&D
SG&A
D&A
SBC
Operating cash flow$1.81B
CapEx-$271.0M
Free cash flow$910.0M
Total assets$14.62B
Total liabilities$10.52B
Total equity$4.11B
Cash & equivalents$1.34B
Long-term debt$5.90B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.11B
Net cash-$4.56B
Current ratio0.8
Debt/Equity1.4
ROA4.9%
ROE17.3%
Cash conversion2.5%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricSAEActivity
Op margin7.6%3.1% medp25 1.2% · p75 6.8%top quartile
Net margin4.9%2.0% medp25 0.7% · p75 4.1%top quartile
Gross margin30.1%26.1% medp25 17.2% · p75 32.0%above median
CapEx / revenue-1.9%-2.5% medp25 -4.6% · p75 -1.4%above median
Debt / equity144.0%56.0% medp25 16.8% · p75 121.1%top quartile
Observations
IR observations
Mean price target53.05 ILS
Median price target53.05 ILS
High price target54.00 ILS
Low price target52.10 ILS
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Last actual revenue14,489,000,000 ILS
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-23 05:15 UTC#e1989de1
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 07:13 UTCJob: 49362194